source
- STAT+: Johnson & Johnson advances IBD therapy, despite trial missA closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.STAT · 3mo ago↗ source
- Vertex drops mRNA cystic fibrosis program over 'tolerability' issuesVertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering th…Endpoints · 3mo ago↗ source
- STAT+: French regulator fines Novo and Lilly over weight loss ad campaignsFrance's medicines regulator has fined Novo Nordisk and Eli Lilly over their weight loss ad campaigns.STAT · 3mo ago↗ source